An Open-label Multi-center, Randomized Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2013
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 14 Jul 2012 New source identified and integrated (German Clinical Trials Register DRKS00004014).
- 09 Dec 2010 Actual patient number is 460 and additional locations identified according to ClinicalTrials.gov.